Aventis Triumphs In Patent Suit Over ALS Drug

Law360, New York (July 27, 2007, 12:00 AM EDT) -- A Delaware federal court has buried Impax Laboratories Inc.'s efforts to market a generic version of a Sanofi-Aventis U.S. LLC treatment for Lou Gehrig's disease by validating a patent for the Aventis drug Rilutek.

Impax announced Friday that the Delaware federal court has validated the patent on the grounds of anticipation. The court had already thrown out Impax's claims that the patent was acquired by inequitable conduct.

Impax had argued that previous research covered by another Aventis patent, U.S. Patent Number 5,236,940, had anticipated the use...
To view the full article, register now.